Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» FDA advisers unanimously back GlaxoSmithKline drug for kidney cancer, despite liver risks
FDA advisers unanimously back GlaxoSmithKline drug for kidney cancer, despite liver risks
FDA advisers unanimously back GlaxoSmithKline drug for kidney cancer, despite liver risks
Submitted by
admin
on October 6, 2009 - 10:45am
Source:
Yahoo/AP
News Tags:
FDA
GSK
kidney cancer
pazopanib
Headline:
FDA advisers unanimously back GlaxoSmithKline drug for kidney cancer, despite liver risks
Do Not Allow Advertisers to Use My Personal information
